FDA OKs ZEISS MEL 90 Excimer Laser

ZEISS Medical Technology has earned U.S. Food and Drug Administration (FDA) approval for its MEL 90 excimer laser for the indications of myopia, hyperopia, and mixed astigmatism.

The company’s MEL 90 laser integrates into its Corneal Reactive Workflow. It complements the VisuMax 800 with Smile pro to broaden the surgeon’s refractive business with improved patient attraction and positive outcomes, according to ZEISS.

VisuMax obtained FDA approval in January 2024.

MEL 90’s “Triple-A” (advanced ablation algorithm) is a single ablation profile for a range of sphero-cylindrical (SCA) corrections. ZEISS said it provides accuracy, reproducibility, and predictability, and tissue-saving ablation. Preinstalled functions provide further support.

When performing LASIK for myopia at 500 Hz, MEL 90 can intra-operatively ablate one diopter in as little as 1.3 seconds, the company explained. The laser has an active eve tracker with quick response time, with a graphic user interface and option for a second touch screen.

An HD video port, network printer connection, and PDF export capabilities further support workflow.

“The increasing global adoption of laser vision correction reflects the advancements and positive impact the technology continues to have on the quality of life for patients,” said Magnus Reibenspiess, Head of Strategic Business Unit Ophthalmology at ZEISS. “With the integration of the ZEISS MEL 90, surgeons can confidently care for their patients with greater workflow efficiency and performance with enhanced outcomes.”

“ZEISS continues to break new ground as a leader in the LVC market, reflecting our ongoing commitment to and support of U.S. surgeons and patients with the latest refractive innovation that helps set practices apart and provides more options to more patients,” added Andrew Chang, Head of Global Sales for ZEISS. “With the availability of the ZEISS MEL 90 in the U.S. market, surgeons can now offer an integrated workflow of refractive technology to help reach new patients and provide excellent outcomes for them.”